Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus ruxolitinib in treatment-naïve myelofibrosis
2023-506139-13-00Phase 3Authorised
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised trial of selinexor in myelofibrosis (MF) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Spleen volume reduction ≥35% at Week 24 and Absolute mean change in total symptom score at Week 24. Planned start Jan 2024; status: authorised.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2023-506139-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506139-13-00.